The Drug Controller General of India (DCGI) approved a trial of a drug for reducing mortality rate in critically ill COVID-19 patients and the trial is likely to begin at multiple hospitals. The Council of Scientific and Industrial Research (CSIR) through the New Millennium Indian Technology Leadership Initiative (NMITLI) program. Key Points: The drug has been developed by Cadila Pharmaceuticals Limited with the support of Council of Scientific and Industrial Research (CSIR) to treat critically ill patients suffering from Gram-negative bacterial sepsis. About Gram-negative bacterial sepsis:Sepsis is defined as a systemic disease caused by microorganisms or their products in the blood. Bacteremia is the presence of viable organisms in the circulation. Gram negative bacteremia in the critically ill patient is synonymous with gram negative sepsis.
